INTRODUCTION
Numerous avenues of research ranging from basic experimental evidence to population-based observational studies have led to the recognition that CVD has many features of a systemic inflammatory process. 1 Inflammation is a key element of the atherosclerotic process and contributes to all of its stages, from plaque initiation to subsequent growth and eventual rupture.
2,3,4 Highsensitivity C-reactive protein (hsCRP) is an easily measured and widely investigated biomarker of inflammation. It is unclear whether CRP itself directly contributes to the pathophysiology of CVD. Supporting data for a role for CRP in atherothrombosis is limited to in vitro studies and experiments with animal models. 5, 6 Pepys et al. found that specific inhibition of CRP is feasible with a small-molecule synthetic compound [1,6-bis(phosphocholine)-hexane], which produces smaller infarct sizes in rats. 7 Regardless of whether CRP plays a causal role in atherothrombosis, this biomarker has been proposed to be useful for improving CVD-risk prediction.
Although, elevated levels of serum CRP have been reported in patients with CVD, the serum levels of CRP in patients with NSTEMI ACS is unknown. The purpose of the study was to determine whether the serum levels of CRP are higher in patients with NSTEMI ACS as compared to healthy controls.
MATERIALS AND METHODS:
This cross-sectional study was carried out in the Department of Biochemistry with collaboration of Department of Internal Medicine, B.P. Koirala Institute of Health Sciences, Dharan, Nepal. The study population was comprised of Group I and Group II. Group I was comprised of twenty-five age-matched healthy men as controls and Group II was comprised of forty-five NSTEMI ACS patients admitted to our coronary care unit with unstable angina or acute myocardial infarction. Inclusion criteria were typical chest pain and non ST elevation in at least two contiguous electrocardiographic leads, elevated cardiac troponin levels, or angina at rest following myocardial infarction within 2 weeks in patients with unstable angina. Fasting blood samples were collected and serum levels of CRP were measured by using highly sensitivity immunoassay rate method technology. The assay is reported to have a minimum detectable concentration of 0.00035 mg/L. At a concentration of 0.003 mg/L, our inter-assay precision was 7.4% (n=20). figure 1 . Group II showed a 253% higher level of hsCRP as compared to Group I subjects.
STATISTICAL ANALYSIS:

Figure1: hsCRP levels in controls and cases
DISCUSSION:
In the present study, we investigated the levels of hsCRP in patients with NSTEMI ACS as the inflammatory marker. As a result of our analysis, hsCRP level is significantly higher in patients group as compared to normal healthy adults (p<0.005). In the Kennon et al. study, 8 CRP levels were evaluated in patients with ACS and non-ST elevation on admission and after 12, 24 and 48 h; they shifted from a mean of 4.5 to one of 4.72, 7.79 and 9.99 respectively, with a statistically significant difference between patients taking and not taking aspirin prior to the onset of symptoms. In the study of James et al.
9
, CRP was assessed in patients with ACS (angina, positive troponin (Tn) T or Tn I tests and ST depression ˃5 mm) at baseline and after 8, 16, 24, 36 and 48 h after randomization. CRP levels ranged between 0 to 489 mg/dl. Cusack et al. 10 reported mean CRP levels in ACS at baseline, 6, 24, 48 h and 7 days: there was an increase after 48 h and a reduction below baseline levels after 7 days. In patients with NSTEMI, CRP plasmatic concentration significantly increased at 48 and 72 h, even if administration of tirofiban lowered rise of CRP levels.
11
Similar release curves were identified by other authors also in patients with AMI 12 with peak concentration on third day after MI.
13
In patients with UA, persistent or worsening symptoms and signs of ischemia despite full medical therapy indicate a poor prognosis, 14, 15, 16 However, at the time of hospital admission, it is not possible to predict whether UA will remit or progress to myocardial infarction, because the causes of instability and the mechanisms underlying its evolution are not known. A role for inflammation in UA is suggested by histological studies of unstable coronary plaques, 17,18 evidence of the systemic release of thromboxanes and leukotrienes, 19, 20 and the presence of activated circulating leukocytes.
21,22
Furthermore, increased concentrations of plasma CRP, the prototypal acutephase reactant, have been reported in some patients with UA 23,24 in patients with coronary artery disease and other types of angina, 25 and in 20 percent of patients who have an AMI within six hours after the onset of symptoms, before any elevation of myocardial enzyme levels in serum. 26 The acutephase reactants are very sensitive, although nonspecific, markers of inflammation. In patients with severe UA, elevated plasma levels of CRP are associated with an unfavourable shortterm prognosis. 
CONCLUSION:
The results demonstrate that the serum levels of CRP are higher in patients with NSTEMI ACS as compared to controls. Serum CRP levels are elevated in patients with NSTEMI ACS and may contribute to the inflammation and thrombosis associated with acute coronary syndrome.
Assuming that plasma hsCRP reflects future risk of CVDs, intervention which reduces CRP may be effective in preventing the occurrence of cardiovascular events. Serial evaluation of CRP plasmatic concentration may help in risk stratification of patients with ACS.
